Siegfried Schmitt, PhD, vice-president, Technical at Parexel, answers questions on the use and benefits of real-world ...

In the conclusion of this three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

In this continuation of a three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

Pharmaceutical Technology® spoke with Juliana Maynard, PhD, Head of Translational Imaging, at Medicines Discovery Catapult, ...

Pfizer re-balances weight loss portfolio with Metsera, Bristol Myers Squibb and Roche make Breast cancer progress, and ...

“Integrating PAT enables right-first-time production, as real-time data and predictive models minimize errors and ensure ...

Alvin Jogasuria, ProBio; Matthew Lunning, University of Nebraska Medical Center; and Carl Schoellhammer, DeciBio, go behind ...

AI and ML enhance drug discovery by rapidly screening compounds and predicting ADMET properties, reducing resource commitment ...

The 100% tariff on imported drugs will pressure pharma companies to build manufacturing sites in the US or face significant ...

Pharmaceutical Technology® spoke with Bryan Miller, Director of Scientific and Technical Operations at Crown Bioscience UK, ...

Pharma news on AI's role in drug development, new FDA/EMA guidance, clinical advances, MFN pricing agreements, and ongoing quality control challenges.

The FDA draft guidance "Considerations for Complying with 21 CFR 211.110" raises points to consider regarding drug products ...